Killer dendritic cells: IKDC and the others.
Tumors can regress as a result of invading myeloid and lymphoid cells that act in concert. Although the myeloid cells are widely recognized as antigen presenters and lymphoid cells as classical effectors, recent evidence revealed the capacity of dendritic cells (DC) to kill tumor cells. The functional concept of 'natural killer (NK) myeloid DC' is supported by mouse and human in vitro data that may be clinically relevant because human killer DC can contribute to tumor shrinking during topical therapy with toll-like receptor (TLR) agonists. Whether tumor killing by DC is a 'catalyzing' step for efficient crosspresentation and/or a promoting step for an immunogenic cell death pathway remains an open question. We also discuss how interferon-producing killer DC (IKDC) may participate in the control of tumor progression.
INSERM U805, Villejuif, France.
Mathieu
M
Bonmort
Marc
M
Dalod
Grégoire
G
Mignot
Evelyn
E
Ullrich
Nathalie
N
Chaput
Laurence
L
Zitvogel
D000818:Animals; D003602:Cytotoxicity, Immunologic / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D007372:Interferons / Q000276:immunology*; D019409:Interleukin-15 / Q000276:immunology / Q000378:metabolism; D007694:Killer Cells, Natural / Q000276:immunology* / Q000378:metabolism; D009369:Neoplasms / Q000276:immunology* / Q000378:metabolism; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000378:metabolism; D051193:Toll-Like Receptors / Q000276:immunology
D019409:Interleukin-15; D051193:Toll-Like Receptors; D007372:Interferons